CLINICAL

SYNERGISTIC BIOSTIMULATION

The role of oral collagen supplementation in enhancing clinical outcomes

DR BARBARA KUBICKA

Dr Barbara Kubicka, also known as “The Collagen Queen,’ is an aesthetic doctor and regenerative medicine expert, with over 15 years’ experience in skin health and collagen-treatments. She combines clinical expertise with a holistic approach to healthy ageing, specialising in collagen stimulation, skin rejuvenation, and evidence-led wellness strategies.

CLINICAL AUDIT METHODOLOGY

Patients included in this retrospective clinical audit were adults who underwent collagen biostimulation treatment at a single specialist aesthetic clinic between May 1, 2024 and May 1, 2026. Eligible patients had age-related facial volume loss and/or skin laxity and completed the planned treatment protocol together with the scheduled follow-up. Patients with incomplete treatment, insufficient follow-up documentation, or missing clinical photographs were excluded.

TREATMENT PROTOCOL

Patients received treatment with collagen biostimulatory agents (PLLA or PDLLA) according to standard clinical protocols. The treatment schedule, injection technique and product selection were determined according to clinical indication but followed the same principles throughout the audit.

Patients in the combination group additionally received oral hydrolysed collagen supplementation at a daily dose of 20 g together with 1,000 mg liposomal vitamin C. Supplementation commenced at the beginning of treatment and continued throughout the treatment period and follow-up.

TREATMENT INTERVALS

Biostimulation sessions were performed approximately every six weeks, according to routine clinical practice. Patients were reviewed after completion of the treatment protocol, with outcomes assessed at approximately six months following the initial treatment.

OUTCOME ASSESSMENT

Clinical outcomes were evaluated using standardised photography before treatment and at follow-up. All photographs were assessed by the same experienced clinician, who remained consistent throughout the audit to minimise inter-observer variability. Clinical outcomes were categorised as:

• Excellent: visible improvement in skin quality, firmness and volume restoration.

• Moderate: visible improvement present but less than expected.

• Minimal: slight clinical improvement with limited aesthetic benefit.

• No improvement: no visible change.

LIMITATIONS

This audit was conducted as part of routine clinical practice and not designed as a randomised prospective clinical trial. It represents a retrospective single-centre clinical audit with a relatively small sample size (n = 30). Outcome assessment relied on clinical photography and expert evaluation without validated objective scoring systems or blinded assessors. The study included different collagen biostimulators according to individual clinical indications, introducing potential treatment heterogeneity.

The findings reflect real-world clinical practice and generate an important hypothesis that systemic collagen supplementation may enhance the response to injectable collagen biostimulation. Larger prospective, randomised controlled studies are required to confirm these observations.

COLLAGEN BIOLOGY

Collagen is the principal structural protein of the extracellular matrix and constitutes approximately 30% of the total protein within the human body. Multiple collagen subtypes contribute to skin and connective tissue homeostasis. Type I collagen provides tensile strength and dermal density; Type III is associated with elasticity and early tissue repair; Type V regulates collagen fibril assembly and contributes to hair follicle architecture; while Types II and X are involved primarily in cartilage integrity and tissue remodelling. These collagen types interact within a complex extracellular matrix, supporting the rationale for multi-collagen supplementation in regenerative medicine.

ORAL COLLAGEN MECHANISM

Hydrolysed collagen is enzymatically processed into low molecular weight peptides that are efficiently absorbed within the gastrointestinal tract. Rather than acting simply as structural building blocks, bioactive peptides such as prolylhydroxyproline (Pro-Hyp) and glycyl-prolylhydroxyproline (Gly-Pro-Hyp) function as signalling molecules capable of stimulating fibroblast activity, promoting extracellular matrix synthesis and enhancing endogenous collagen production.

VITAMIN C

Vitamin C is an essential cofactor for collagen biosynthesis because it enables hydroxylation of proline and lysine residues during collagen formation, thereby stabilising the collagen triple helix. Inadequate vitamin C impairs collagen maturation and tissue repair. Liposomal formulations may improve bioavailability and cellular uptake compared with conventional preparations, making vitamin C an important component of comprehensive regenerative treatment protocols alongside collagen supplementation and injectable biostimulation.

SPECIAL PATIENT POPULATIONS

Certain patient groups appear particularly susceptible to suboptimal responses following collagen biostimulation because of reduced systemic collagen synthesis or diminished protein availability. Patients receiving GLP-1 receptor agonists frequently consume less protein and may experience accelerated loss of lean soft tissue. Similarly, postmenopausal women demonstrate a well-established reduction in collagen production associated with declining oestrogen levels. Individuals with low body mass index, smokers and patients with poor dietary protein intake may possess reduced regenerative capacity. In these populations, systemic collagen supplementation may provide additional substrate to support extracellular matrix remodelling and optimise the biological response to injectable collagen stimulators.